Alvotech to Report Financial Results for the First Quarter of 2026
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) will release first quarter 2026 financial results on Wednesday, May 6, 2026 after U.S. market close. A webcast with live Q&A is scheduled for Thursday, May 7, 2026 at 08:00 EST (12:00 GMT).
Slides and presentation materials will be posted on the company's investor events page before the call. Registration links and investor/media contact emails are provided for access and inquiries.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Earnings date notice | Neutral | +2.4% | Scheduled Q4 and full-year 2025 earnings release and call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling for ALVO was followed by a modest positive move, while the subsequent earnings release saw a negative reaction.
Over recent months, ALVO has moved from routine disclosures into more material milestones. An earlier earnings date notice on Mar 4, 2026 preceded Q4 and FY 2025 results. Those results on Mar 18, 2026 showed rising revenue and EBITDA but drew a negative price reaction. Subsequent filings, including the 2025 Form 20-F, highlighted a shift to profitability alongside substantial ongoing risks, framing today’s Q1 2026 earnings-date announcement within a period of active financial and regulatory communication.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
REYKJAVIK, ICELAND (April 24, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close.
The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST).
- To listen to the webcast, please register here: Q1 2026 webcast registration
- To participate in the Q&A, please register here: Q1 2026 conference call registration
Slides and other material will be made available on investors.alvotech.com/events before the call.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.
